Amneal Pharmaceuticals, Inc. (AMRX)

USD 7.69

(-4.71%)

Net Debt Summary of Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.'s latest annual net debt in 2023 was 2.65 Billion USD , down -5.68% from previous year.
Amneal Pharmaceuticals, Inc.'s latest quarterly net debt in 2024 Q2 was 2.68 Billion USD , down -0.66% from previous quarter.
Amneal Pharmaceuticals, Inc. reported annual net debt of 2.81 Billion USD in 2022, up 7.26% from previous year.
Amneal Pharmaceuticals, Inc. reported annual net debt of 2.62 Billion USD in 2021, up 1.11% from previous year.
Amneal Pharmaceuticals, Inc. reported quarterly net debt of 2.69 Billion USD for 2024 Q1, up 1.52% from previous quarter.
Amneal Pharmaceuticals, Inc. reported quarterly net debt of 2.71 Billion USD for 2023 Q3, down -1.15% from previous quarter.

Annual Net Debt Chart of Amneal Pharmaceuticals, Inc. (2023 - 2015)

Historical Annual Net Debt of Amneal Pharmaceuticals, Inc. (2023 - 2015)

Year	Net Debt	Net Debt Growth
2023	2.65 Billion USD	-5.68%
2022	2.81 Billion USD	7.26%
2021	2.62 Billion USD	1.11%
2020	2.59 Billion USD	-0.59%
2019	2.61 Billion USD	5.52%
2018	2.47 Billion USD	75.67%
2017	1.41 Billion USD	5254.3%
2016	-27.36 Million USD	55.2%
2015	-61.08 Million USD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	2.68 Billion USD	-0.66%
2024 Q1	2.69 Billion USD	1.52%
2023 Q3	2.71 Billion USD	-1.15%
2023 Q2	2.74 Billion USD	1.51%
2023 FY	2.65 Billion USD	-5.68%
2023 Q1	2.7 Billion USD	-3.92%
2023 Q4	2.65 Billion USD	-2.16%
2022 Q4	2.81 Billion USD	1.77%
2022 Q3	2.77 Billion USD	-1.31%
2022 Q2	2.8 Billion USD	5.69%
2022 FY	2.81 Billion USD	7.26%
2022 Q1	2.65 Billion USD	1.05%
2021 Q4	2.62 Billion USD	8.14%
2021 Q1	2.46 Billion USD	-5.06%
2021 Q2	2.63 Billion USD	6.94%
2021 FY	2.62 Billion USD	1.11%
2021 Q3	2.43 Billion USD	-7.91%
2020 Q3	2.68 Billion USD	-1.04%
2020 Q1	2.87 Billion USD	9.92%
2020 Q4	2.59 Billion USD	-3.01%
2020 FY	2.59 Billion USD	-0.59%
2020 Q2	2.7 Billion USD	-5.77%
2019 Q2	2.72 Billion USD	-0.01%
2019 FY	2.61 Billion USD	5.52%
2019 Q4	2.61 Billion USD	2.13%
2019 Q3	2.56 Billion USD	-6.13%
2019 Q1	2.72 Billion USD	10.09%
2018 Q4	2.47 Billion USD	-8.55%
2018 FY	2.47 Billion USD	75.67%
2018 Q3	2.7 Billion USD	-0.31%
2018 Q2	2.71 Billion USD	89.64%
2018 Q1	1.43 Billion USD	1.62%
2017 Q3	-19.34 Million USD	0.0%
2017 Q1	31.72 Million USD	215.91%
2017 Q4	1.41 Billion USD	7390.56%
2017 FY	1.41 Billion USD	5254.3%
2016 FY	-27.36 Million USD	55.2%
2016 Q4	-27.36 Million USD	0.0%
2015 FY	-61.08 Million USD	0.0%

Peer Net Debt Comparison of Amneal Pharmaceuticals, Inc.

Name	Net Debt	Net Debt Difference
Bausch Health Companies Inc.	21.44 Billion USD	87.599%
Catalent, Inc.	4.69 Billion USD	43.414%
Emergent BioSolutions Inc.	765.8 Million USD	-247.216%
Elanco Animal Health Incorporated	5.42 Billion USD	50.959%
Perrigo Company plc	3.32 Billion USD	19.961%
Teva Pharmaceutical Industries Limited	16.92 Billion USD	84.291%
Zoetis Inc.	4.76 Billion USD	44.163%